| __timestamp | MannKind Corporation | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 79435000 |
| Thursday, January 1, 2015 | 29674000 | 162644000 |
| Friday, January 1, 2016 | 14917000 | 237939000 |
| Sunday, January 1, 2017 | 14118000 | 168435000 |
| Monday, January 1, 2018 | 8737000 | 173797000 |
| Tuesday, January 1, 2019 | 6900000 | 113842000 |
| Wednesday, January 1, 2020 | 6248000 | 747027000 |
| Friday, January 1, 2021 | 12312000 | 2534508000 |
| Saturday, January 1, 2022 | 19721000 | 1235278000 |
| Sunday, January 1, 2023 | 31283000 | 737502000 |
Unleashing insights
In the competitive world of biotechnology, innovation is the lifeblood of success. MannKind Corporation and Novavax, Inc. have been at the forefront of this race, each with a unique approach to research and development (R&D) spending. Over the past decade, Novavax has consistently outpaced MannKind, investing nearly 25 times more in R&D by 2021. This surge is particularly evident in 2020, when Novavax's R&D expenses skyrocketed by over 500% compared to the previous year, driven by their COVID-19 vaccine development efforts. Meanwhile, MannKind's R&D spending has remained relatively stable, with a slight uptick in 2023. This disparity highlights Novavax's aggressive push in vaccine innovation, while MannKind maintains a steady focus on its core areas. As the biotech landscape evolves, these investment strategies will undoubtedly shape the future of healthcare innovation.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Novavax, Inc.
R&D Insights: How Pfizer Inc. and Novavax, Inc. Allocate Funds
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds
Comparing Innovation Spending: Pharming Group N.V. and Novavax, Inc.
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Opthea Limited vs MannKind Corporation
Comparing Innovation Spending: TG Therapeutics, Inc. and Novavax, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.
Analyzing R&D Budgets: Amphastar Pharmaceuticals, Inc. vs Novavax, Inc.